MannKind | MNKD - Selling And Administration Expenses


MannKind reported $29.09M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Adma Biologics USD 23.05M 320K Sep/2025
BioCryst Pharmaceuticals USD 80.47M 15.39M Dec/2024
Eli Lilly USD 3.13B 391.3M Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
Karyopharm Therapeutics USD 27.19M 442K Dec/2024
MacroGenics USD 9.9M 600K Sep/2025
MannKind USD 29.09M 2.53M Sep/2025
Merck USD 2.85B 215M Dec/2025
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Novavax USD 66.95M 34.05M Sep/2024
Novo Nordisk DKK 2.86B 13.25B Jun/2025
Pfizer USD 4.08B 894M Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Xencor USD 87.78M 72.66M Sep/2025